Das Produkt wurde korrekt in den Warenkorb gelegt.

discount label
5Fam-FLPSDCFPSV-OH
3D-Ansicht

Biosynth logo

5Fam-FLPSDCFPSV-OH

Ref. 3D-PP44412

Unbestimmte GrößeNachfragen
Voraussichtliche Lieferung in Vereinigte Staaten, am Montag 28. Oktober 2024

Produktinformation

Name:
5Fam-FLPSDCFPSV-OH
Synonyme:
  • 5Fam-Phe-Leu-Pro-Ser-Asp-Cys-Phe-Pro-Ser-Val-OH
Beschreibung:

Peptide 5Fam-FLPSDCFPSV-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using 5Fam-FLPSDCFPSV-OH include the following: Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules V Ramakrishna, JF Treml, L Vitale - The Journal of , 2004 - journals.aai.orghttps://journals.aai.org/jimmunol/article/172/5/2845/82483 Identification of O-glycosylated decapeptides within the MUC1 repeat domain as potential MHC class I (A2) binding epitopes T Ninkovic, L Kinarsky, K Engelmann, V Pisarev - Molecular , 2009 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0161589008007001 TAPBPR alters MHC class I peptide presentation by functioning as a peptide exchange 1 catalyst 2 SS Duriez, J Trowsdale , JE Deane, T Elliott, H Louise - catalyst - researchgate.nethttps://www.researchgate.net/profile/Louise-Boyle-2/publication/282653273_TAPBPR_alters_MHC_class_I_peptide_presentation_by_functioning_as_a_peptide_exchange_catalyst/links/561cac1608aea8036724a573/TAPBPR-alters-MHC-class-I-peptide-presentation-by-functioning-as-a-peptide-exchange-catalyst.pdf Functional characterization of CTL against gp100 altered peptide ligands SO Dionne, MH Smith, FM Marincola - Cancer Immunology , 2003 - Springerhttps://link.springer.com/article/10.1007/s00262-002-0358-3 Her-2/neu altered peptide ligand-induced CTL responses: implications for peptides with increased HLA affinity and T-cell-receptor interaction SO Dionne, CE Myers, MH Smith, DF Lake - Cancer Immunology , 2004 - Springerhttps://link.springer.com/article/10.1007/s00262-003-0439-y Tumor-derived Peptides Modified at HLA-A* 0201 Binding Residues Elicit Cytotoxic T Lymphocyte Responses SO Dionne - 2002 - search.proquest.comhttps://search.proquest.com/openview/483128c5dd868a08c07fa4bfea671d20/1?pq-origsite=gscholar&cbl=18750&diss=y Towards chemically altered peptide ligands as T cell-targeted influenza vaccines SKR Huber, JJ Luimstra - for peptide , 2015 - scholarlypublications https://scholarlypublications.universiteitleiden.nl/access/item%3A2919352/download#page=106 Chemical modification of influenza CD8+ T-cell epitopes enhances their immunogenicity regardless of immunodominance SK Rosendahl Huber, JJ Luimstra, J van Beek - PloS one, 2016 - journals.plos.orghttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0156462 Immune responses against conserved influenza epitopes: lessons for peptide S Rosendahl Huber - Scand J Immunol, 1997 - scholarlypublications https://scholarlypublications.universiteitleiden.nl/access/item%3A2919359/download Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model MWJ Schreurs, AAO Eggert, AJ de Boer, JLM Vissers - Cancer Research, 2000 - AACRhttps://aacrjournals.org/cancerres/article-abstract/60/24/6995/506996 Promiscuous binding of invariant chain-derived CLIP peptide to distinct HLA-I molecules revealed in leukemic cells MM Van Luijn , AA Van de Loosdrecht, MH Lampen - PLoS , 2012 - journals.plos.orghttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0034649 Mannose Receptor Targeting of Tumor LZH Jones, J Goldstein, PK Wallace , T Connolly - J , 2004 - researchgate.nethttps://www.researchgate.net/profile/John-Connolly-26/publication/8686870_Mannose_Receptor_Targeting_of_Tumor_Antigen_pmel17_to_Human_Dendritic_Cells_Directs_Anti-Melanoma_T_Cell_Responses_via_Multiple_HLA_Molecules/links/0deec52a85690a9f4b000000/Mannose-Receptor-Targeting-of-Tumor-Antigen-pmel17-to-Human-Dendritic-Cells-Directs-Anti-Melanoma-T-Cell-Responses-via-Multiple-HLA-Molecules.pdf Aberrant glycosylation of anchor-optimized MUC1 peptides can enhance antigen binding affinity and reverse tolerance to cytotoxic T lymphocytes LB Pathangey, V Lakshminarayanan, VJ Suman - Biomolecules, 2016 - mdpi.comhttps://www.mdpi.com/2218-273X/6/3/31 The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism JMM Den Haan , LM Meadows, W Wang, J Pool - Science, 1998 - science.orghttps://www.science.org/doi/abs/10.1126/science.279.5353.1054 TER ICD CLIP - Alternative HLA class-I peptide , 2012 - scholarlypublications https://scholarlypublications.universiteitleiden.nl/access/item%3A2920218/download Specific T cell responses against minor histocompatibility antigens cannot generally be explained by absence of their allelic counterparts on the cell surface HM Bijen, C Hassan, MGD Kester, GMC Janssen - , 2018 - Wiley Online Libraryhttps://analyticalsciencejournals.onlinelibrary.wiley.com/doi/abs/10.1002/pmic.201700250 Exosomes as a tumor vaccine: enhancing potency through direct loading of antigenic peptides DH Hsu, P Paz, G Villaflor, A Rivas - Journal of , 2003 - journals.lww.comhttps://journals.lww.com/immunotherapy-journal/fulltext/2003/09000/exosomes_as_a_tumor_vaccine__enhancing_potency.7.aspx Insights on the HLA-Binding Peptidome in Cancer DF Lake - The Enzymes, 2017 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1874604717300252 Variation in cytotoxic T-lymphocyte responses to peptides derived from tyrosinase-related protein-2 CE Myers, SO Dionne, K Shakalya, D Mahadevan - Human immunology, 2008 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0198885907004831 CTL recognition of a novel HLA-A* 0201-binding peptide derived from glioblastoma multiforme tumor cells CE Myers, P Hanavan, K Antwi, D Mahadevan - Cancer Immunology , 2011 - Springerhttps://link.springer.com/article/10.1007/s00262-011-1032-4 Custom designed MHC binding peptides for cancer immunotherapy CE Myers - 2009 - search.proquest.comhttps://search.proquest.com/openview/cc8c77cae25dbecfcd3f327dccb3cf47/1?pq-origsite=gscholar&cbl=18750 TAPBPR alters MHC class I peptide presentation by functioning as a peptide exchange catalyst C Hermann, A Van Hateren, N Trautwein, A Neerincx - Elife, 2015 - elifesciences.orghttps://elifesciences.org/articles/9617 Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1,-A3,-A11, and-B7 AH Bakker , R Hoppes, C Linnemann - Proceedings of the , 2008 - National Acad Scienceshttps://www.pnas.org/doi/abs/10.1073/pnas.0709717105

Hinweis:
Unsere Produkte sind nur für Laborzwecke. Für jede andere Verwendung, bitte melden sie sich bei uns.
Marke:
Biosynth
Langzeitlagerung:
Hinweise:

Chemische Eigenschaften

MDL:
Schmelzpunkt:
Siedepunkt:
Flammpunkt:
Dichte:
Konzentration:
EINECS:
Merck:
HS-Code:

Gefahrenhinweise

UN-Nummer:
EQ:
Klasse:
H-Sätze:
P-Sätze:
Flugverbot:
Gefahrenhinweis:
Verpackungsgruppe:
LQ:

Technische Anfrage zu: 3D-PP44412 5Fam-FLPSDCFPSV-OH

Bitte verwenden Sie stattdessen den Warenkorb, um ein Angebot oder eine Bestellung anzufordern

Wenn Sie ein Angebot anfordern oder eine Bestellung aufgeben möchten, legen Sie stattdessen die gewünschten Produkte in Ihren Warenkorb und fordern Sie dann ein Angebot oder eine Bestellung an aus dem Warenkorb. Es ist schneller, billiger und Sie können von den verfügbaren Rabatten und anderen Vorteilen profitieren.

* Obligatorische felder
Willkommen bei CymitQuimica!Wir verwenden Cookies, um Ihren Besuch zu verbessern. Wir schließen Werbung nicht ein.

Bitte beachten Sie unsere Cookie-Richtlinie  für weitere Details oder passen Sie Ihre Einstellungen unter “Konfigurieren” an.